How many medications do doctors in primary care use? An observational study of the DU90% indicator in primary care in England

Chiamaka Chiedozie,¹,² Mark E Murphy,¹ Tom Fahey,¹ Frank Moriarty

ABSTRACT

Aim To apply the drug utilisation 90% (DU90%) indicator (the number of unique drugs which makes up 90% of a doctor’s prescribing) to general practitioner (GP) practices prescribing in England to examine time trends, practice-level variation, and relationships with practice characteristics, prescribing costs and low-value prescribing.

Study design Retrospective cohort study.

Setting Primary care in England, using publicly available prescribing data available from the National Health Service (NHS) digital platform for 2013–2017.

Participants All general practices in England (n=7620).

Primary and secondary outcome measures The DU90% was calculated on an annual basis for each practice based on medication British National Formulary codes. Low-value prescribing was defined using NHS 2017 guidance (including lidocaine plasters, liothyronine, omega-3 supplements).

Descriptive statistics were generated per year on time trends and practice-level variation in the DU90%. Multilevel linear regression was used to examine the practice characteristics (relating to staff, patients and deprivation of the practice area).

Results Among 7620 practices, mean DU90% ranged from 130.0 to 131.0 across study years, and regarding variation between practices, there was a 1.4-fold difference between the lowest and highest 5% of practices. A range of medications were included in the DU90% of virtually all practices, including atorvastatin, levothyroxine, omeprazole, ramipril, amlodipine, simvastatin and aspirin. A higher volume of prescribing was associated with a lower DU90%, while having more patients, higher proportions of patients who are women or aged ≥45 years, higher number of GPs working in the practice and being in a more deprived area were associated with a higher DU90%.

Practices in higher quintiles of DU90% had higher levels of priority prescribing and prescribing costs. A higher volume of prescribing was defined using NHS 2017 guidance (including lidocaine plasters, liothyronine, omega-3 supplements).

Conclusions GP practices typically use 130 different medications in the bulk of their prescribing. Higher DU90% was associated with higher levels of low-priority prescribing and prescribing costs. Increasing use of personal formularies may enhance prescribing quality and reduce costs.

INTRODUCTION

Prescribing is the most common health-care intervention in developed countries, however decisions to prescribe or continue a medication for a patient are complex, with many factors that must be considered. These include a medication’s indication, dosage, frequency, duration of use, adverse effects, contraindications and interactions with other medications or conditions an individual may have.¹ Doctors can develop expertise in only a certain number of drugs, and so may have to consult information sources when considering others they are less familiar with. For this reason, the WHO’s Guide to Good Prescribing suggests that prescribers should develop a personal list (ie, drugs they have chosen to prescribe regularly which they are familiar with that are their priority option for given indications).² This should support the selection of the right drug for each patient in the relatively short time that may be available to consider this during a consultation. While a small number of preferred drugs may be feasible for specialist prescribers, this may prove challenging for general practitioners (GPs) as generalists prescribing a wide range of treatments,³ and who often manage all medications for patients, including those initiated by specialists in secondary care.⁴-⁶

Use of a relatively limited number of core drugs, which a prescriber is an expert in, may reduce task complexity in treatment decisions and potentially be associated with a higher quality of prescribing and reduced
errors. The availability of many alternatives with similar therapeutic effects can compromise patient safety through potential confusion between drugs within a class but with different properties or dosage. Mitigating this risk of confusion is one basis for developing a core drug list for undergraduate and postgraduate prescribing education in the UK. Some countries have implemented restricted formularies or essential medicines lists on this basis, such as the ‘Wise List’ in Sweden and local formularies in the UK, to help facilitate clinicians in prescribing the most effective, safe and appropriate medications for their patients.

The drug utilisation 90% (DU90%) is a measure recommended by the WHO for drug utilisation research, and represents the number of unique drugs which makes up 90% of a doctor’s prescribing. The number, as well as the specific drugs, in this segment, may serve as simple indicators of the quality of drug prescribing. It has been used to provide feedback to GP practices on their prescribing patterns for quality assurance. A DU90% segment with a large number of drugs may indicate use of medications which a prescriber sees infrequently, which may increase the risk of suboptimal prescribing. Similarly, a segment with limited number of drugs may indicate more rational prescribing. Wettermark et al assessed the usefulness of DU90% as a tool for indicating prescribing quality, and found high acceptance of this among GPs in Sweden who regarded DU90% profile as clear, relevant and useful for improving prescribing quality.

The aims of this study are:

- To characterise the DU90% indicator in prescribing data from GP practices in England, by assessing time trends, variation between practices and relationship with practice characteristics.
- To assess the relationship between DU90% and prescribing deemed to be low-value care and prescribing costs.

**METHODS**

**Study design, setting and participants**

This is a repeated cross-sectional study of GP practices in England and is reported in line with the Strengthening the Reporting of Observational Studies in Epidemiology statement. It used publicly available prescribing data available from the National Health Service (NHS) digital platform. This provides monthly statistics of prescribing of different medicines aggregated at the level of GP practices for all practices in England. The data relate to NHS prescriptions issued by any prescribing staff in GP practices in England and is reported in line with the Strength Reporting of Observational Studies in Epidemiology statement. The DU90% indicator was calculated on an annual basis for each GP practice using a modified approach. The number of prescriptions in each year per medicine was summarised at the practice level. Unique medicines were identified using the first nine digits of the British National Formulary (BNF) code, which identifies each chemical substance. In line with previous studies which excluded products without a WHO Defined Daily Dose (DDD), certain non-oral pharmaceutical products were excluded before analysis based on their BNF codes (see online supplemental table 1). Medicines were arranged in descending order of total number of prescriptions for each medicine within a practice and the DU90% calculated represents the number of medicines where the cumulative sum of prescriptions is >90% of all prescriptions issued by the practice. This differs from the typical approach to calculating the DU90% using WHO DDDs to express volume of prescribing. However, due to a lack of reliable means of assigning WHO DDD to each BNF chemical substance code, we represented volume of prescribing using number of prescriptions.

Characteristics of GP practices were of interest as explanatory variables potentially associated with the DU90%. These included what Clinical Commissioning Group (CCG) the practice is part of, the deprivation of the area the practice is located in, number of registered patients, and age and sex distribution of registered patients, quality of care indicated by the QOF score and practice workforce (ie, the number of full-time equivalent (FTE) GPs, age and sex distribution of GPs, and whether the practice has a registrar GP). CCGs are health commissioning organisations in England, and prescribing by GP practices may be influenced by the CCG they are part of through formularies developed by CCGs, or CCG-level medicines optimisation teams.

**Data sources**

Prescribing data from NHS England captures the number of prescription items for each product that was dispensed in the specified month per practice. It also includes the product’s BNF code, the quantity of dosage units dispensed per product, the net ingredient cost (NIC) and the actual cost per product. GP practice workforce, registered patient data, and overall QOF performance for each year for included practices were downloaded from the NHS digital website and summarised at the practice level. For deprivation, the Index of Multiple Deprivation (IMD) for 2015 is provided for geographical areas (lower level super output areas or LSOAs) by the Department for Communities and Local Government.
The index captures the following dimensions of deprivation: income, employment, education, health, crime, access to housing and services, and living environment. Practices were assigned the IMD decile of the LSOA they were located in based on their postcode. Public Health England also provides estimates for GP practices based on the population weighted average of the IMD scores of the LSOAs where the practice population lives (based on 2016 populations), although this had higher level of missingness than practice postcode IMD.

**Results**

A total of 7620 GP practices were included in this study (see online supplemental figure 1 for flow diagram), with the number included during each study year shown in table 1, along with practice, registered patient and GP workforce characteristics. Between 153 and 158 medicines made up 90% of overall prescribing for included practices during the study period. At practice level, the mean DU90% ranged from 130.0 to 131.0 across study years, and varied by between threefold and fivefold depending on the year. However, trimming at the 5% level, the equivalent span was approximately 1.4 across study years (see online supplemental table 3). The vast majority of GP practices had a DU90% within 2 SDs of the mean, with 4% falling between 2 and 3 SDs, and less than 1% having a DU90% greater than 3 SDs from the mean. Figure 1 shows the distribution of practice by DU90% across years and also indicates variation was low and remained stable with time.

There was a decreasing linear trend in DU90% across years (p<0.001). Fitting a mixed linear regression model with random intercepts for CCGs and practices, and study year as a fixed effect (table 2, model 1), there was a statistically significant reduction in DU90% across years, although of small magnitude. Based on variance partition coefficients, 24% of variance was between CCGs, 70% between practices and 6% within practices.

Model 2 found higher numbers of registered patients and a higher proportion of patients aged 45 years or over were both associated with higher DU90% (3.89, 95% CI 3.66 to 4.12, more medicines in the DU90% per additional 4600 registered patients; and 1.99, 95% CI 1.85 to 2.13, higher per 2.3% increase in proportion of female patients). Higher proportion of patients aged 45 years and over and high deprivation were both also associated with increased DU90%, although the magnitude was smaller. Higher total number of prescription items and overall QOF score were both associated with a lower DU90%. When GP workforce characteristics were considered, more GP FTEs or presence of a GP registrar were both associated with higher DU90%, while proportion of GPs aged 45 years and over was associated with a reduction. Findings in sensitivity analysis using weighted practice population IMD (online supplemental table 4) were broadly similar, with the proportion of patients aged 45 years and over no longer being significantly associated with DU90%. 

**Analysis**

First, baseline characteristics of included GP practices were calculated. To characterise variation in DU90%, we plotted the distribution of practices by their DU90% by year. We also determined the proportion of practices with a DU90% between 2 and 3 SD from the mean, and more than 3 SD from the mean, as well as the extremal quotient per year (trimmed at the 5% level). We tested for a linear trend across years using the nptrend function in Stata, and assessed differences between years using a multilevel linear regression model.

We fitted a multilevel linear regression model with random intercepts at the CCG and practice levels. We determined the total variance, as well as the variance between CCGs, between practices and within practices by calculating the variance partition coefficient. Standardised versions of covariates (ie, centred on their mean with an SD of 1) were added to this regression model as fixed effects to assess factors associated with the DU90%. First, patient and practice characteristics were added, followed by GP workforce characteristics. The regression equation for the final model is shown in online supplemental box 1. A sensitivity analysis was conducted using IMD based on weighted practice population, instead of IMD based on practice postcode.

Medicines included in the DU90% segment were characterised for both 2013 and 2017. We determined the medicines that feature in the DU90% segment of the most practices by year, and those that constituted the greatest volume of prescriptions within the DU90% by year. We determined the proportion of DU90% medicines across BNF chapters (ie, physiological systems) and average number of DU90% medicines within common drug classes with multiple drugs (statins, proton-pump inhibitors (PPIs), ACE inhibitors, angiotensin II receptor blockers, dihydropyridine calcium channel blockers, beta blockers, selective serotonin reuptake inhibitors (SSRIs), penicillins and opioids).

The original DU90% includes an assessment of guideline adherence within the DU90% segment (proportion of medicines in the segment recommended in guidelines). As there is no national guideline for England for recommended medicines, we assessed prescribing of items which the NHS recommends should not be routinely prescribed in primary care due to low effectiveness, poor cost-effectiveness or being low priority (online supplemental table 2). We summarised both the proportion of all prescribing considered low priority, and the proportion of low priority prescribing within the DU90% for each practice, expressed in terms of prescriptions and costs. Lastly, we assessed whether practices’ DU90% (divided into five groups based on quintiles) was associated with differences in prescribing costs, low-priority item prescribing, BNF chapters and number of agents within common drug classes.
Table 3 compares medicines included in the DU90% of practices in 2013 and 2017. The distribution of these medicines across BNF chapters (physiological systems) was similar over the study period, and mean number of agents within common drug classes in a practice’s DU90% was also stable. Online supplemental tables 5 and 6 list the medicines included in practices’ DU90% segments in 2013 and 2017, respectively, and show that the medicines making up the highest proportions of prescribing were similar in these years. From approximately 1250 medicines (ie, chemical substances based on 9-digit BNF codes), 652 different medicines were included in the DU90% across included practices for 2013, and 606 for 2017. In 2017, a range of medicines were included in the DU90% of the vast majority (≥99.0%) of practices across statins (atorvastatin, simvastatin), PPIs (lansoprazole, omeprazole), cardiovascular medicines (ramipril, amlodipine, bisoprolol fumarate, aspirin), inhalers (salbutamol, beclometasone dipropionate), central nervous system (CNS) agents (paracetamol, amitriptyline, citalopram) and others (levothyroxine sodium, metformin, folic acid, oral prednisolone). The agents that accounted for the greatest proportion of items prescribed in practices which included them in their DU90% were atorvastatin (4.1%), levothyroxine sodium (3.4%) and omeprazole (3.4%).

Considering prescribing in 2017, the mean NIC per 1000 items per practice was £7835 (SD 1472), and on average, the DU90% accounted for 67.8% of costs. The low-priority items constituted a mean of 0.48% of all prescribing and 0.26% of prescribing in the DU90%, which equated to 2.02% of total costs and 1.19% of DU90% costs. Table 4 divides practices by quintiles of DU90% and illustrates that higher DU90% is related to higher costs, a higher proportion of costs within the DU90%, as well as higher low-priority prescribing both overall and within the DU90%, regardless of expression as prescription items or costs. Regarding types of medications, the percentage of cardiovascular, respiratory and endocrine medicines within the DU90% decreased with higher DU90%, while the percentage of CNS and infections medicines increased with higher DU90% (figure 2). The mean number of agents within each class increased across quintiles. The greatest relative increase was for opioids, PPIs and calcium channel blockers, whereas the increases were of lesser magnitude for SSRIs, ACE inhibitors and beta blockers. Online supplemental figure
Table 2 Characteristics associated with practice DU90% in multilevel linear regression

|                          | β coefficient (95% CI) |
|--------------------------|------------------------|
|                          | Model 1                | Model 2                | Model 3                |
| **Year (reference 2013)**|                        |                        |                        |
| 2014                     | −0.63 (−0.73 to −0.53) | −0.58 (−0.68 to −0.48) | −0.57 (−0.67 to −0.47) |
| 2015                     | −0.99 (−1.09 to −0.89) | −1.07 (−1.17 to −0.97) | −1.03 (−1.13 to −0.92) |
| 2016                     | −1.10 (−1.20 to −1.00) | −1.26 (−1.37 to −1.16) | −1.20 (−1.32 to −1.09) |
| 2017                     | −1.25 (−1.35 to −1.15) | −1.53 (−1.64 to −1.42) | −1.49 (−1.61 to −1.37) |
| Total prescription items* | −0.98 (−1.24 to −0.73) | −1.39 (−1.66 to −1.11) |                        |
| IMD decile               | 0.39 (0.30 to 0.49)    | 0.35 (0.26 to 0.44)    |                        |
| Overall QOF percentage*  | −0.07 (−0.13 to −0.01) | −0.07 (−0.13 to −0.01) |                        |
| Registered patients*     | 3.89 (3.66 to 4.12)    | 4.45 (4.19 to 4.70)    |                        |
| Proportion of patients aged ≥45 years* | 0.26 (0.03 to 0.50)    | 0.51 (0.27 to 0.75)    |                        |
| Proportion of female patients* | 1.99 (1.85 to 2.13) | 2.04 (1.89 to 2.18) |                        |
| GP FTEs*                 |                        | 0.27 (0.16 to 0.37)    |                        |
| GP proportion aged ≥45 years* | −0.12 (−0.18 to −0.05) |                        |                        |
| GP proportion female*    | 0.03 (−0.04 to 0.09)   |                        |                        |
| Any registrar            | 0.22 (0.07 to 0.37)    |                        |                        |
| **Variance (VPC)**       |                        |                        |                        |
| CCG                      | 38.7 (24.0)            | 29.7 (24.7)            | 29.4 (24.9)            |
| Practice                 | 112.9 (70.0)           | 80.5 (67.2)            | 79.1 (67.0)            |
| Residual                 | 9.7 (6.0)              | 9.6 (8.0)              | 9.5 (8.1)              |

*β coefficients represent change in DU90% per change of 1 SD in covariate value (78 651 in total prescription items, 6.7 percentage points (pp) in overall QOF percentage, 4586 in registered patients, 2.3 pp in proportion of female patients, 3 in GP FTEs, 10.3 pp in proportion of patients aged 45 years and over, 25.9 pp in proportion of female GPs, and 28.7 pp in proportion of GPs aged 45 years and over).

CCG, Clinical Commissioning Group; DU90%, drug utilisation 90%; FTEs, full-time equivalents; GP, general practitioner; IMD, Index of Multiple Deprivation; QOF, Quality and Outcomes Framework; VPC, variance partition coefficient.

2 shows the distribution of practices by the number of agents within drug classes included in their DU90%, split across quintiles of DU90%. Online supplemental tables 7 and 8 list the individual medicines included in practices’ DU90% segment in 2017 for the bottom and top quintile of DU90%.

**DISCUSSION**

Our study found that typically 130 unique medications account for 90% of the prescribing volume of GP practices in England, and variation, which was primarily between practices, was relatively low. The mean DU90% of 130 per GP practice in this study is similar to previous studies which reported means ranging from 128 to 165 drugs in practices’ DU90%, and variation similarly in the range of twofold. 3,16,20

We found that greater numbers of patients and a greater proportion of patients aged 45 years and above were associated with a higher DU90%. Controlling for the number of prescriptions, a large patient population would more likely require a greater variety of medications within the DU90%. Another explanation is that more patients in a practice would require more GPs who may make different prescribing choices. The relationship between patient population size and DU90% persisted after adjustment for GP workforce variables. Similar to the large patient population, the prevalence of multimorbidity increases with age, 21–23 and so for older people it may be more likely that they require multiple medications or that first-line treatments may be unsuitable for them due to interactions with their other drugs or conditions. 24 Hence, a higher proportion of older patients may also contribute to a higher DU90%. A higher proportion of female patients was also associated with a higher DU90% although to a lesser degree, again explained perhaps by research showing women are more likely to have multiple conditions and take more medicines. 22,23 There was also a relationship between higher DU90% and high deprivation. Deprivation is associated with poorer health outcomes and greater multimorbidity, 21 and potentially less time available for GPs to optimise or rationalise prescribing due to the increased health needs of the population and resulting demand. 25

Taking practice workforce characteristics into consideration, more FTE GPs and the presence of a GP registrar were both associated with a reduction in the DU90%. More GPs working in a practice and their individual prescribing habits are likely to contribute to variation...
in prescribing and a higher DU90%. Presence of a GP registrar indicates practices which may be more actively engaged in education and practice development. Our findings are somewhat consistent with recent research which found GP training practices had higher patient satisfaction across several domains,26 27 had higher QOF scores,27 higher scores for both level and quality of services,28 prescribed fewer antibiotics overall and broad-spectrum antibiotics.29

Future research could consider applying the DU90% in specific therapeutic domains. Previous domain-specific research in primary care has focused on priority or high-risk drug classes, particularly antibiotics, where variation in the overall number of agents, broad-spectrum agents and non-first-line agents in the DU90% has been examined.30–31 Variation in DU90% profiles of non-steroidal anti-inflammatory drugs32–34 and CNS agents has also been examined.35 36 Audit and feedback is an important intervention for quality improvement.40 Implementing the DU90% within practice management software systems or Open-Prescribing.net, for example, could provide prescribers with an opportunity to benchmark themselves against other GP practices.41 Specifically, feedback on a practice’s DU90% within specific therapeutic domains and the agents that predominate could be used in conjunction with local formularies to identify areas where prescribing could be optimised. Previous studies have found positive attitudes among prescriber to feedback incorporating their DU90%.16 42 43

There is potential that information on medications used commonly by many practices could be considered in formulary development or updates. Previous research demonstrates that practices can vary substantially in their response to changes in prescribing recommendations.44 Therefore, the current predominant practice may be a consideration where there is little clinical or cost-effectiveness difference between complementary drugs. Information on predominant medications can also be useful in education. The development of a ‘starter’ formulary for trainee prescribers has been an important step, as during training, students may be exposed to varied prescribing practices.8 10 11 However, even more experienced prescribers, depending on their pharmacology training,5 could also benefit from rationalising their personal formulary to enhance quality of prescribing and potentially reduce errors.45 In total, approximately 600 medicines featured in the DU90% of at least one practice, representing about half of medications included. Although GPs within a single practice may be using a core group of drugs themselves, coordinating prescribing among their colleagues in the same practice may be beneficial where GPs may be renewing prescriptions initiated by other prescribers in the practice.46 This is supported by evidence that the number of prescribers is an important factor in the risk of inappropriate drug combinations.47

While clinicians may be encouraged to focus on prescribing a smaller range of medicines, measures to reduce the variety of drugs prescribed have been applied via restricted formularies or reimbursement lists.9 The ‘Wise List’ is a formulary of essential medicines in the Stockholm region of Sweden, and is regarded as trustworthy and useful by primary care doctors.48 It can be regarded as effect, as adherence to its recommendations in primary care has increased from 80% in 2000 to 90% in 2015, with practice variation decreasing from 32% to 13%.12 The ability to restrict the number of medications on the market at the level of individual countries is limited in Europe by membership of the European Union (EU) and measures such as the European Medicines Agency’s centralised approval process. For example, Sweden experienced a substantial growth in the number of pharmaceutical products on its market after joining the EU in 1995 and adopting EU regulations.3

### Table 3: Medication categories within DU90% in 2013 and 2017

| BNF chapters | 2013 n (%) | 2017 n (%) |
|--------------|------------|------------|
| Gastrointestinal | 93358 (9.4) | 89182 (9.6) |
| Cardiovascular | 245279 (24.7) | 228782 (24.6) |
| Respiratory | 84843 (8.5) | 81301 (8.8) |
| Central nervous system | 262184 (26.4) | 241016 (25.9) |
| Infections | 80851 (8.1) | 67143 (7.2) |
| Endocrine | 81299 (8.2) | 83688 (9.0) |
| Obstetric, urinary tract disorders | 54706 (5.5) | 53129 (5.7) |
| Malignancy and immunosuppression | 4563 (0.5) | 4857 (0.5) |
| Nutrition and blood | 25785 (2.6) | 26274 (2.8) |
| Musculoskeletal | 58485 (5.9) | 50283 (5.4) |
| Anaesthesia | 3191 (0.3) | 3169 (0.3) |

| Drug classes | Mean (SD) agents in DU90% per practice |
|--------------|---------------------------------------|
| Statins | 3.42 (0.65) |
| PPIs | 2.74 (0.74) |
| ACE inhibitors | 3.60 (0.65) |
| ARBs | 3.13 (0.96) |
| CCB | 3.02 (0.86) |
| BB | 3.65 (0.80) |
| SSRIs | 3.96 (0.71) |
| Penicillins | 2.90 (0.32) |
| Opioids | 4.81 (1.47) |

ARBs, angiotensin II receptor blockers; BB, beta blocker; BNF, British National Formulary; CCB, calcium channel blocker; DU90%, drug utilisation 90%; PPIs, proton-pump inhibitors; SSRIs, selective serotonin reuptake inhibitors.

---

Chiedozie C, et al. BMJ Open 2021;11:e043049. doi:10.1136/bmjopen-2020-043049
Strengths and limitations

A limitation of our study is that data were available only at the GP practice level, rather than at the level of individual prescribers. Hence, a high DU90% may be optimal if different prescribers in a practice have expertise that covers a wider breadth of medicines, and this is reflected in the finding of a relationship between more GPs and higher DU90%. However, there was still a relationship between higher DU90% and low-value prescribing and medication costs. While previous studies have assessed the proportion of guideline-recommended medications with practices’ DU90%, we were limited by the lack of national formulary. Although local formularies do exist, these are not all publicly available, or in a form which allows the information in them to be easily reused. Publication of local formularies in machine readable, interoperable formats, including coded medication details (such as BNF, Anatomical Therapeutic Chemical (ATC) classification or SNOMED (Systematized NOmenclature of MEDicine)), would facilitate further drug utilisation research. A further limitation is that we lacked detailed information about the registered patient populations for each practice, and thus full adjustment for differences in case mix between practices was not possible. However, we did account for the age and sex profile of practices’ patients. Other factors such as exposure to pharmaceutical representatives, or the level of prescriptions initiated in specialist care, could also explain some variation in the DU90% and prescribing costs.

This study is the first to our knowledge to examine trends in the DU90% over time, and to apply this measure in an English setting, and provides evidence that GP practices with higher DU90% tended to have higher prescribing costs and more prescribing of low-priority care (ie, low effectiveness, poor cost-effectiveness or being low priority). The DU90% could be implemented into GP practice prescribing analysis in the future and used for audit and feedback purposes to help optimise prescribing practice, through OpenPrescribing, for example. This could be tailored using details of local formularies to also include a measure of adherence to recommendations within the DU90% segment. Such tools which may help doctors optimise their prescribing are important to maximise medication benefits and reduce harms. This is

| Table 4 | Costs, low-priority item prescribing, BNF chapters and drug classes in 2017 across quintiles of DU90% |
|---------|---------------------------------------------------------------------------------------------------|
|         | 1st                  | 2nd                  | 3rd                  | 4th                  | 5th                  |
| Net ingredient cost (NIC) per 1000 prescriptions (£) | 6274 (1202) | 6881 (1118) | 7263 (1157) | 7909 (1263) | 8842 (1369) |
| DU90% NIC as a percentage of total NIC | 67.4 (4.0) | 67.7 (3.5) | 67.7 (3.2) | 68.2 (2.9) | 68.3 (2.8) |
| Low-priority items as a percentage of total items | 0.46 (0.29) | 0.47 (0.28) | 0.46 (0.23) | 0.50 (0.24) | 0.53 (0.21) |
| Low-priority items as a percentage of DU90% items | 0.25 (0.28) | 0.25 (0.28) | 0.24 (0.23) | 0.27 (0.24) | 0.28 (0.21) |
| Low-priority NIC as a percentage of total NIC | 1.56 (1.20) | 1.93 (1.33) | 2.01 (1.33) | 2.18 (1.27) | 2.46 (1.37) |
| Unique agents within classes in DU90%, mean (SD) |
| Statins | 3.13 (0.73) | 3.39 (0.67) | 3.52 (0.61) | 3.64 (0.55) | 3.74 (0.50) |
| PPIs | 2.53 (0.67) | 2.78 (0.72) | 2.99 (0.75) | 3.09 (0.72) | 3.25 (0.70) |
| ACE inhibitors | 3.18 (0.72) | 3.29 (0.66) | 3.40 (0.65) | 3.47 (0.61) | 3.55 (0.61) |
| Angiotensin receptor blockers | 2.52 (0.72) | 2.66 (0.70) | 2.70 (0.69) | 2.78 (0.73) | 2.97 (0.71) |
| Calcium channel blockers | 2.54 (0.87) | 2.87 (0.85) | 3.06 (0.85) | 3.13 (0.84) | 3.25 (0.84) |
| Beta blockers | 3.28 (0.66) | 3.37 (0.64) | 3.45 (0.66) | 3.44 (0.63) | 3.49 (0.69) |
| SSRI | 3.43 (0.66) | 3.71 (0.66) | 3.86 (0.67) | 3.94 (0.68) | 4.20 (0.66) |
| Penicillins | 2.68 (0.51) | 2.87 (0.39) | 2.93 (0.34) | 2.97 (0.29) | 3.01 (0.29) |
| Opioids | 3.76 (1.53) | 4.70 (1.28) | 5.17 (1.18) | 5.43 (1.10) | 5.75 (1.04) |

BNF, British National Formulary; DU90%, drug utilisation 90%; PPIs, proton-pump inhibitors; SSRI, selective serotonin reuptake inhibitors.

Figure 2 Percent of DU90% prescriptions by BNF chapter (therapeutic domain) across quintiles of DU90%. BNF, British National Formulary; CNS, central nervous system; DU90%, drug utilisation 90%.
a clear priority globally, reflected in the WHO’s current Third Global Patient Safety Challenge, ‘Medication without Harm’.59

Twitter Mark E Murphy @dmarkmurphy and Frank Moriarty @FrankMoriary

Contributors FM conceived the study, CC, MEM, TF and FM designed the study. CC collated the data. CC and FM conducted the analysis. All authors interpreted the findings. CC and FM drafted the manuscript and all authors critically revised the manuscript.

Funding This study was funded by the Health Research Board in Ireland (HRB) through the Summer Student Scholarships (grant no. SS/2018/080) and the HRB Centre for Primary Care Research (HRC/2014/01), and supported by the Royal College of Surgeons in Ireland Undergraduate Research Summer School.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval As this study used publicly available data aggregated at the general practitioner practice-level, ethical approval was not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. The data that support the findings of this study are openly available in Zenodo at https://doi.org/10.5281/zenodo.3894539.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Mark E Murphy http://orcid.org/0000-0002-4240-5327
Tom Fahey http://orcid.org/0000-0002-5896-5783
Frank Moriarty http://orcid.org/0000-0001-9838-3625

REFERENCES

1 Aronson JK. Rational prescribing, appropriate prescribing. Br J Clin Pharmacol 2004;57:229–30.
2 De Vries T, Henning RH, Hogerzeil HV. Guide to Good Prescribing - A practical manual. World Health Organisation, Geneva, Switzerland, 1994.
3 Bergman U, Popa C, Tomson Y, et al. Drug utilization 90%--a simple method for assessing the quality of drug prescribing, Eur J Clin Pharmacol 1998;54:113–8.
4 Marx G, Püschel K, Ahrens D. [Polypharmacy; a dilemma in primary care? Results of group discussions with general practitioners]. Gesundheitswesen 2009;71:339–48.
5 Sinnott C, Mc Hugh S, Browne J, et al. Gps’ perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research. BMJ Open 2013;3:e003610.
6 Aliabadi NJ, Nishtala PS, Magan D, et al. General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study. Int J Clin Pract 2016;70:261–76.
7 Chinhurausinga V, Lanson LN, Brucks M, et al. Physician prescribing decisions: the effects of situational involvement and task complexity on information acquisition and decision making. Soc Sci Med 1993;36:1473–82.
8 De Vries TPM, Daniels JMA, Mulder CW, et al. Should medical students learn to develop a personal formulary? an international, multicentre, randomised controlled study. Eur J Clin Pharmacol 2008;64:641–6.
9 Sofat R, Cremer S, Ferner RE. Drug and therapeutics committees as guardians of safe and rational medicines use. Br J Clin Pharmacol 2020;86:10–12.
10 Baker E, Pryce Roberts A, Wilde K, et al. Development of a core drug list towards improving prescribing education and reducing errors in the UK. Br J Clin Pharmacol 2011;71:190–8.
11 Audis S, Burrage DR, Lonsdale DO, et al. The ‘top 100’ drugs and classes in England: an updated ‘starter formulary’ for trainee prescribers. Br J Clin Pharmacol 2018;84:2562–71.
12 Erikson J, Gustafsson LL, Ateva K, et al. High adherence to the ‘wise List’ treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open 2017;7:e014345.
13 Reynolds DJM, Fajemisin O, Wilds S. Local formularies. Br J Clin Pharmacol 2012;74:640–3.
14 King MA, Roberts MS. The influence of the pharmaceutical benefits scheme (PBS) on inappropriate prescribing in Australian nursing homes. Pharm World Sci 2007;29:39–42.
15 Dhananjay K, N. K, Sahu S, et al. Drug utilization 90%: an innovative method in assessing quality of drug prescription with specific reference to non-steroidal anti-inflammatory drugs prescription. Int J Basic Clin Pharmacol 2016;5:1746–51.
16 Wettermark B, Pehrsson A, Jinnerot D, et al. Drug utilisation 90% profiles--a useful tool for quality assessment of prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf 2003;12:499–510.
17 von Elm E, Altman DG, Egger M, et al. The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e229.
18 Okasha D, Kassiss I, Haddad S, et al. General medications utilization and cost patterns in hospitalized children. Pharmacy Practice 2009;7:54–8.
19 Ashworth M, White P, Jongama H, et al. Antibiotic prescribing and patient satisfaction in primary care in England: cross-sectional analysis of national patient survey data and prescribing data. Br J Gen Pract 2016;66:e40–6.
20 Wettermark B, Bergman U, Krakau I. Using aggregate data on dispensed drugs to evaluate the quality of prescribing in urban primary health care in Sweden, Public Health 2006;120:451–61.
21 Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet 2012;380:37–45.
22 Violan C, Fouquet-Boure O, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One 2014;9:e102149.
23 Nguyen H, Manolova G, Daskalopoulou C, et al. Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies. J Comorb 2019:235042X1987093.
24 Dumbreck S, Flynn A, Nairn M, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2013;346:f3580.
25 Mercer SW, Watt GCM. The inverse care law: clinical primary care encounters in deprived and affluent areas of Scotland. Ann Fam Med 2007;5:503–10.
26 Ashworth M, Schofield P, Durbaba S, et al. Patient experience and the role of postgraduate GP training: a cross-sectional analysis of national patient survey data in England. Br J Gen Pract 2014:64:e168–77.
27 Weston C, Ahluwalia S, Bassett P, et al. Gp training practices in England: a description of their unique characteristics based on national data. Education for Primary Care 2017;28:313–8.
28 van den Homberg P, Schalk-Soecker S, Kramer A, et al. Are family practice trainers and their host practices any better? comparing practice trainers and non-trainers and their practices. BMC Fam Pract 2013;14.
29 Ahluwalia S, Sadak M, Ashworth M. Antimicrobial prescribing in post-graduate training practices: a cross-sectional study of prescribing data in general practices in England. Educ Prim Care 2018;29:139–43.
30 Malo S, Bjerrum L, Feja C, et al. The quality of outpatient antimicrobial prescribing: a comparison between two areas of northern and southern Europe. Eur J Clin Pharmacol 2014;70:347–53.
31 Horvat O, Mijatović V, Milijasević B, et al. Are there striking differences in outpatient use of antibiotics between South Baska district, Serbia, and some Scandinavian countries? Front. Public Health 2018;6:91.
32 Pradipta I, Kartikawati A, Hartanto H, et al. Three years of antibiotic consumption in Indonesian Community Health Centers: The application of anatomical therapeutic chemical/defined daily doses and drug utilization 90% method to monitor antibiotic use. J Fam Community Med 2015;22:101–5.
33 Baan EJ, Janssens HM, Kerckerta T, et al. Antibiotic use in children with asthma: cohort study in UK and Dutch primary care databases. BMJ Open 2018;8:e022979.
34 Abbasian H, Hajimolaali M, Yektadoost A, et al. Antibiotic utilization in Iran 2000-2016: pattern analysis and benchmarking with organization for economic co-operation and development countries. J Res Pharm Pract 2019;8:162–7.
35 Barozzi N, Sketris I, Cooke C, et al. Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and nova Scotia (Canada). Br J Clin Pharmacol 2009;68:106–15.
36 Calasan J, Mijatović V, Horvat O, et al. The outpatient utilization of non-steroidal anti-inflammatory drugs in South Bačka district, Serbia. Int J Clin Pharm 2011;33:246–51.
37 Mijatović V, Calasan J, Horvat O, et al. Consumption of non-steroidal anti-inflammatory drugs in Serbia: a comparison with Croatia and Denmark during 2005–2008. Eur J Clin Pharmacol 2011;67:203–7.
38 Smith AJ, Tett SE. How do different age groups use benzodiazepines and antidepressants? analysis of an Australian administrative database. 2003-6. Drugs Aging 2009;26:113–22.
39 Marković-Peković V, Stojsavljević-Šatar S, Škrbić R. Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. Eur J Clin Pharmacol 2010;66:177–86.
40 Iversen N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012;13:CD000259.
41 Walker AJ, Curtis HJ, Croker R, et al. Measuring the impact of an open web-based prescribing data analysis service on clinical practice: cohort study on NHS England data. J Med Internet Res 2019;21:e10929.
42 Vlahović-Palcevski V, Wettermark B, Prpić I, et al. Attitudes to feedback with drug utilisation 90% (DU90%) profiles among prescribers in Rijeka, Croatia. Pharmacoepidemiol Drug Saf 2004;13:725–7.
43 Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care 2009;17:179–89.
44 Walker AJ, Pretis F, Powell-Smith A, et al. Variation in responsiveness to warranted behaviour change among NHS clinicians: novel implementation of change detection methods in longitudinal prescribing data. BMJ 2019;29:15205.
45 Moorthy V, Harvey I, Brawn R, et al. A study of factors associated with cost and variation in prescribing among GPs. Fam Pract 2000:17:36–41.
46 Bjerrem L, Bergman U. Wide variation in the number of different drugs prescribed by general practitioners. A prescription database study. Scand J Prim Health Care 2000;18:94–8.
47 Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Do too many cooKs spoil the broth? multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ 1996;154:1177–84.
48 Erikson J, Ovesjö M-L, Vallin M, et al. Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee’s list of recommended essential medicines (the ‘Wise List’). Eur J Clin Pharmacol 2018:74:131–8.
49 Watkins C, Harvey I, Carthy P, et al. Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey. Qual Saf Health Care 2003;12:29–34.
50 Sheikh A, Dhingra-Kumar N, Kelley E, et al. The third global patient safety challenge: tackling medication-related harm. Bull World Health Organ 2017;95:546–546A.